Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jan 2018 Primary endpoint (Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales) has been met as per the results published in the Journal of the American Academy of Dermatology
30 Jan 2018 Results (n=885) of pooled analysis of REVEAL 1 and REVEAL 2 trials assessing safety and efficacy published in the Journal of the American Academy of Dermatology
24 May 2017 Results from this and one other study (NCT02132117) assessing the Impact Assessment for Rosacea Facial Redness (IA-RFR) outcome, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com